HomeAI · summaries
Storia in 5 fonti
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition - Personalis (NASDAQ:PSNL), Tempu
Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD market.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Tempus to acquire cancer test maker Personalis for $1.5B
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
- ·
fiercebiotech.com
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology. | Tempus is boosting its cancer offerings with a…
